SSRIs for Hot Flashes: A Systematic Review and Meta-Analysis of Randomized Trials
- 1.2k Downloads
Hot flashes are the most commonly reported vasomotor symptom during the peri- and early post-menopausal period.
To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials.
A comprehensive literature search was conducted of MEDLINE™, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus through March 2013. Two independent reviewers selected studies and extracted data. Random effects meta-analysis was used to pool outcomes across studies, and Bayesian mixed treatment methods were used to rank SSRIs in terms of effectiveness.
We included a total of 11 randomized controlled trials with good methodological quality enrolling 2,069 menopausal and post-menopausal women (follow-up 1–9 months, mean age 36–76 years, mean time since menopause 2.3–6.6 years). Compared with placebo, SSRIs were associated with a statistically significant decrease in hot flash frequency (difference in means −0.93; 95 % CI −1.46 to −0.37; I2 = 21 %) and severity assessed by various scales (standardized difference in means −0.34; 95 % CI −0.59 to −0.10; I2 = 47 %). Adverse events did not differ from placebo. Mixed treatment comparison analysis demonstrated the superiority of escitalopram compared to other SSRIs in terms of efficacy.
SSRI use is associated with modest improvement in the severity and frequency of hot flashes but can also be associated with the typical profile of SSRI adverse effects.
KEY WORDSSSRI hot flashes menopause
- 2.National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med. 2005;142(12 Pt 1):1003–13.Google Scholar
- 12.Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration; updated March 2011.Google Scholar
- 14.Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;18(22):3748–57.PubMedGoogle Scholar
- 25.Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2012.Google Scholar
- 30.Akhavan S, Zandvakili F, Arab M, Karimi H, Gharibi F. Comparison of the therapeutic effects of fluoxetine, citalopram, estrogen and progesterone and placebo in the treatment of hot flushes in perimenopausal women. Scientific Journal of Kurdistan University of Medical Sciences. 2011;16(3):31–8.Google Scholar
- 32.Simon JA, Sanacora G, Bhaskar S, Lippman J. Safety and efficacy of low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms (VMS) associated with menopause: A 24-week, randomized, placebo-controlled phase 3 study. Menopause. 2012;19(12):1371.Google Scholar
- 33.Kaunitz A, Sanacora G, Bhaskar S, Lippman J. Safety and efficacy of low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms (VMS) associated with menopause: A 12-week, randomized, placebo-controlled phase 3 study. Menopause. 2012;19(12):1389.Google Scholar
- 36.Ensrud KE, Joffe H, Guthrie KA, Larson JC, Reed SD, Newton KM, et al. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause. 2012;19(8):848–55.PubMedCentralPubMedCrossRefGoogle Scholar
- 40.Reid R, Blake J, Abramson B, Khan A, Senikas V, Fortier M. Menopause and Osteoporosis Update 2009. SOGC Clinical Practice Guidelines. 2009;31(1):Supplement 1.Google Scholar
- 41.Rees MCP, Panay N. Alternatives to HRT for the Management of Symptoms of the Menopause (SAC Opinion Paper 6). 2010.Google Scholar